ArticleJournal of geriatric oncology2014
Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates.
Article in Journal of geriatric oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03992352 (Composite Health Assessment Risk Model), which is not on this map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Frailty in Patients With Hematologic Malignancies and Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2026Pooled it
- Frailty screening in dermato-oncology practice: a modified Delphi study and a systematic review of the literature.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Pooled it
- Geriatric assessment in older patients with a hematologic malignancy: a systematic review.Haematologica · 2020Pooled it
- Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.Blood advances · 2023Trial
- Functional Status as Measured by Geriatric Assessment Predicts Inferior Survival in Older Allogeneic Hematopoietic Cell Transplantation Recipients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Trial
- Conditioning regimen with a 75% dose of standard busulfan/cyclophosphamide plus fludarabine before cord blood transplantation in older patients with AML and MDS.International journal of hematology · 2019Trial
- Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes.Blood cancer journal · 2026Article
- Comprehensive geriatric assessment (CGA) scale does not effectively identify elderly AML patients suitable for intensive induction chemotherapy - a multicenter study from Polish Adult Leukemia Group.Annals of hematology · 2026Article
- HCT Frailty Scale (HCT-FS) for assessing frailty in adult candidates for allogeneic haematopoietic cell transplantation: an international prospective, observational cohort study.EClinicalMedicine · 2026Article
- Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with Hematological Malignancies.Yonago acta medica · 2025Review
- Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704.Blood advances · 2025Observational
- Frailty assessment and outpatient pre-habilitation for adults undergoing allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2025Article
- Allogeneic Transplantation for Older Adults.Advances in experimental medicine and biology · 2025Review
- Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study.Bone marrow transplantation · 2024Article
- Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care.Frontiers in immunology · 2024Article
- How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT.Hematology. American Society of Hematology. Education Program · 2023Article
- HCT frailty scale for younger and older adults undergoing allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2023Article
- Impact of hematopoietic cell transplant frailty scale on transplant outcome in adults.Bone marrow transplantation · 2023Article
- Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant.JCO oncology practice · 2023Article
- Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.Transplantation and cellular therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveOlder patients who receive hematopoietic cell transplantation (HCT) may be at risk for adverse outcomes due to age-related conditions or frailty. Geriatric assessment (GA) has been used to evaluate HCT candidates but can be time-consuming. We therefore sought to determine the predictive ability of two screening tools, the Vulnerable Elders Survey (VES-13) and the G8, for abnormal GA or frailty. MATERIALS AND
methodsWe enrolled 50 allogeneic HCT candidates age ≥60 years. The GA included measures of medical, physical, functional, and social health. Frailty was defined as 3 or more abnormalities on grip strength, gait speed, weight loss, exhaustion, and activity. We associated baseline characteristics and abnormal GA or frailty. We determined the sensitivity and predictive ability of the VES-13 and G8 for GA and frailty.
resultsOverall, 33 (66%) patients (mean age 65.4 years) had an abnormal GA, and 11 patients (22%) were frail. The G8 screening tool had a higher sensitivity for an abnormal GA (69.7%), and the VES-13 had a higher specificity (100%). Both tools had similar discriminatory ability.
conclusionsOlder HCT candidates had a significant number of deficits on baseline GA and a high prevalence of frailty. Existing screening tools may not be able to replace a full GA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.